Oppenheimer Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective reduced by Oppenheimer from $53.00 to $52.00 in a research report report published on Friday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. Wolfe Research began coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They set a peer perform rating on the stock. Truist Financial increased their price objective on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a buy rating in a research note on Friday, March 1st. Piper Sandler increased their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an overweight rating in a research note on Tuesday, February 27th. Stifel Nicolaus increased their price objective on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a buy rating in a research note on Friday, February 23rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an overweight rating in a research note on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $41.10.

Kymera Therapeutics Trading Up 2.4 %

NASDAQ:KYMR opened at $38.30 on Friday. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31. The stock has a fifty day simple moving average of $38.42 and a 200-day simple moving average of $29.76.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. During the same quarter last year, the firm posted ($0.70) earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. Research analysts forecast that Kymera Therapeutics will post -3.15 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 139,255 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the completion of the sale, the director now directly owns 828,830 shares in the company, valued at $35,001,490.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Jared Gollob sold 46,137 shares of Kymera Therapeutics stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the sale, the insider now directly owns 74,709 shares in the company, valued at $2,652,169.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce Booth sold 139,255 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the sale, the director now owns 828,830 shares of the company’s stock, valued at $35,001,490.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 474,051 shares of company stock worth $19,624,211. Company insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth $78,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Kymera Therapeutics by 33.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock worth $72,000 after purchasing an additional 1,310 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Kymera Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock worth $187,000 after purchasing an additional 1,866 shares during the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth $233,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.